Novanta (NOVT) Earnings Date & Reports

Key Takeaways

• Novanta is scheduled to report third quarter 2026 results after the U.S. market close on Monday, November 9, 2026.
• Company guidance calls for adjusted diluted EPS (earnings per share) of $0.95 to $1.00 and revenue of $300 million to $304 million.
• The company beat expectations in the second quarter, posting adjusted EPS of $0.89 versus a $0.83 consensus and revenue of $265.8 million, up 10.3% year over year.
• The recently closed Riverpoint Medical acquisition is expected to lift reported revenue and broaden medical end-market exposure to roughly 60% of sales.
• Artificial intelligence (AI) related data center applications, about 15% of revenue, remain a key growth variable heading into the report.
• Tariffs and softer precision medicine demand are the primary headwinds investors will be watching.

Earnings Context and Why It Matters

Novanta Inc. is a global supplier of precision technology and motion solutions to medical, life science, and advanced industrial original equipment manufacturers. Its upcoming quarterly earnings report matters because the company has been riding a clear momentum shift: bookings rose 18% year to date, backlog climbed 11%, and new product revenue surged more than 50% in the second quarter. With management raising full-year guidance in August and closing its largest-ever acquisition, the third quarter print will test whether that momentum is sustainable. Investors are watching closely for confirmation of organic growth, margin expansion, and continued traction in AI-driven semiconductor and robotics applications.

Earnings Expectations

For the third quarter of 2026, Novanta has guided to adjusted diluted EPS of $0.95 to $1.00, which sits above the analyst consensus estimate of $0.94. The company's revenue guidance of $300 million to $304 million reflects the contribution from the Riverpoint Medical acquisition, which closed during the second quarter and is expected to be immediately accretive to revenue growth, gross margins, EBITDA (earnings before interest, taxes, depreciation, and amortization), and EPS.

For context, Novanta's second quarter delivered revenue of $265.8 million, up 10.3% year over year with 9% organic growth, and adjusted EPS of $0.89, a 17% increase that beat consensus by $0.06. Adjusted EBITDA rose 16% to $60.7 million, and operating cash flow reached a record $65 million. The first quarter was similarly strong, with revenue up 10.4% and adjusted EPS up 9.5% to $0.81. Investors will be measuring the third quarter against this established trend of beats and improved profitability.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking earnings-driven movers like Novanta, the AI Screener offers a streamlined way to monitor technical setups and sentiment shifts ahead of key reports.

Market Reaction and Investor Sentiment

Sentiment heading into Novanta's third quarter report is constructive but measured. The stock has benefited from a series of beats and a raised full-year outlook, with management pointing to "building momentum" across automation, medical, and AI-linked end markets. Still, investors are weighing several risk factors, including ongoing tariff exposure under Section 232 and Section 301, which management has said is not fully offset by surcharging, and inflationary pressure on supply chain and logistics costs. A weaker book-to-bill ratio of 0.79 in the Medical Solutions segment during the second quarter, attributed to order timing, is another point of scrutiny. The market will look for whether bookings, new product launches, and AI-related demand continue to support the higher guidance range.

Forward Outlook and Key Factors to Monitor

Following the third quarter report, investors should focus on the trajectory of organic growth and whether Novanta sustains the acceleration management has described for the back half of the year. The company raised its full-year 2026 outlook to revenue of approximately $1.130 billion to $1.140 billion, adjusted EBITDA of $273 million to $278 million, and adjusted EPS of $3.68 to $3.74, implying reported revenue growth above 15%.

Several catalysts and risks deserve attention. First, the Riverpoint Medical integration will be a key swing factor, with management expecting it to lift gross margins toward 48% in the third quarter while shifting medical exposure to about 60% of revenue. Second, AI-related data center applications, representing roughly 15% of sales and growing near 20%, could drive continued upside in precision manufacturing and robotics.

On the other side, precision medicine grew only 5% in the second quarter, and management does not expect sustained life sciences recovery until 2027. Tariff costs and input inflation also remain wildcards. Watch for updated commentary on bookings, the book-to-bill ratio, and new product revenue, which are the leading indicators most likely to shape the stock's next move.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations